Published in Am J Pathol on October 01, 2005
Trypsin-mediated enzymatic degradation of type II collagen in the human vitreous. Mol Vis (2013) 0.80
Molecular adhesion between cartilage extracellular matrix macromolecules. Biomacromolecules (2014) 0.79
Preservation of the structure of enzymatically-degraded bovine vitreous using synthetic proteoglycan mimics. Invest Ophthalmol Vis Sci (2014) 0.77
Collagen degradation by tumor-associated trypsins. Arch Biochem Biophys (2013) 0.75
Transport and binding of tumor necrosis factor-α in articular cartilage depend on its quaternary structure. Arch Biochem Biophys (2013) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem (1984) 18.48
Redesigning trypsin: alteration of substrate specificity. Science (1985) 3.70
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
Preparation and characterization of the different types of collagen. Methods Enzymol (1982) 3.12
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
Human collagenase: identification and characterization of an enzyme from rheumatoid synovium in culture. Science (1967) 2.15
Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem (1997) 1.82
Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res (1983) 1.61
Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum (2001) 1.46
The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am (2001) 1.20
Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem (1997) 1.19
Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem (1989) 1.11
Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum (2002) 1.11
DNA synthesis in prolyl 4-hydroxylase positive fibroblasts in situ in synovial tissue. An autoradiography-immunoperoxidase double labeling study. J Rheumatol (1989) 1.08
Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry (2003) 1.04
Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med (1990) 0.99
Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods (1993) 0.96
Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem (2000) 0.96
Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol (1995) 0.93
Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res (1990) 0.92
Human leukocyte collagenase: characterization of enzyme kinetics by a new method. Anal Biochem (1977) 0.92
Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochem J (1988) 0.91
Synovial processes in rheumatoid arthritis. Scand J Rheumatol Suppl (1988) 0.90
Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clin Chem (1994) 0.89
Immunoelectron microscopic demonstration of fibronectin in rheumatoid pannus and at the cartilage-pannus junction. Ann Rheum Dis (1983) 0.86
Fibroblasts in synovitis in rheumatoid arthritis but not in noninflammatory synovial tissue in meniscus lesions express the carboxyterminal domain of procollagen type I. Am J Clin Pathol (1990) 0.81
Urine trypsinogen-2 as marker of acute pancreatitis. Clin Chem (1996) 0.79
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (2009) 3.00
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Fecal microbiota in early rheumatoid arthritis. J Rheumatol (2008) 2.94
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol (2006) 2.88
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol (2007) 2.74
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc (2011) 2.20
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Matrix metalloproteinase-8 (MMP-8) is the major collagenase in human dentin. Arch Oral Biol (2006) 2.09
Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol (2007) 2.09
Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy. J Clin Periodontol (2008) 2.05
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum (2004) 2.03
Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med (2006) 1.97
Hypothermia-treated cardiac arrest patients with good neurological outcome differ early in quantitative variables of EEG suppression and epileptiform activity. Crit Care Med (2009) 1.93
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer (2011) 1.86
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem (2009) 1.82
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol (2003) 1.77
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 1.69
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One (2012) 1.63
Use of polymerase chain reaction to diagnose tuberculous arthritis from joint tissues and synovial fluid. Arch Pathol Lab Med (2004) 1.63
Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol (2010) 1.62
A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol (2012) 1.56
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 1.54
Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum (2011) 1.54
Revision total knee arthroplasty: 1990 through 2002. A review of the Finnish arthroplasty registry. J Bone Joint Surg Am (2006) 1.52
Bacterial components in the synovial tissue of patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction. Arthritis Rheum (2003) 1.52
A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab (2005) 1.51
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther (2010) 1.49
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop (2009) 1.48
Increased expression and processing of ADAM 12 (meltrin-alpha) in osteolysis associated with aseptic loosening of total hip replacement implants. J Rheumatol (2005) 1.46
Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 1.46
Specific immunoassay reveals increased serum trypsinogen 3 in acute pancreatitis. Clin Chem (2011) 1.44
Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol (2013) 1.44
Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs. Clin Rheumatol (2013) 1.42
High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol (2004) 1.41
Corneal innervation and morphology in primary Sjögren's syndrome. Invest Ophthalmol Vis Sci (2003) 1.41
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res (2005) 1.41
Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer (2010) 1.41
Emdogain in carcinogenesis: a systematic review of in vitro studies. J Oral Sci (2010) 1.41
Incidence of prosthetic joint infections after primary knee arthroplasty. J Arthroplasty (2008) 1.37
Mesenchymal stem cells and cardiac repair. J Cell Mol Med (2008) 1.37
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Alterations in corneal sensitivity and nerve morphology in patients with primary Sjögren's syndrome. Exp Eye Res (2008) 1.36
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol (2008) 1.35
Younger age increases the risk of early prosthesis failure following primary total knee replacement for osteoarthritis. A follow-up study of 32,019 total knee replacements in the Finnish Arthroplasty Register. Acta Orthop (2010) 1.34
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer (2010) 1.32
Low rate of infected knee replacements in a nationwide series--is it an underestimate? Acta Orthop (2009) 1.32
The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30
Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res (2005) 1.30
Prevention of deep infection in joint replacement surgery. Acta Orthop (2010) 1.28
Comparative metaproteomics and diversity analysis of human intestinal microbiota testifies for its temporal stability and expression of core functions. PLoS One (2012) 1.28
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update (2006) 1.26
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma (2005) 1.25
DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res (2010) 1.24
Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun (2012) 1.24
Cartilage repair: past and future--lessons for regenerative medicine. J Cell Mol Med (2009) 1.24
Clinical changes in periodontium during pregnancy and post-partum. J Clin Periodontol (2008) 1.23
Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun (2003) 1.23
The effect of subgingival controlled-release delivery of chlorhexidine chip on clinical parameters and matrix metalloproteinase-8 levels in gingival crevicular fluid. J Periodontol (2002) 1.22
Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol (2008) 1.21
Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res (2011) 1.21
Salivary biomarkers of oral health: a cross-sectional study. J Clin Periodontol (2012) 1.19
Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol (2012) 1.19
Alternative materials to improve total hip replacement tribology. Acta Orthop Scand (2003) 1.18
Macrophages-Key cells in the response to wear debris from joint replacements. J Biomed Mater Res A (2013) 1.18
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst (2008) 1.18
Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem (2003) 1.18
Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun (2013) 1.18
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Bioabsorbable miniplating versus metallic fixation for metacarpal fractures. Clin Orthop Relat Res (2003) 1.17
Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. J Periodontal Res (2003) 1.16
Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod (2002) 1.16
Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol (2002) 1.16
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis (2007) 1.15
Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab (2004) 1.14
Amyloidosis-recent developments. Semin Arthritis Rheum (2008) 1.14